Sonnet BioTherapeutics, Inc. (NASDAQ:SONN) | WebDisclosure

Basculer en Français

8295	Companies
114846	Keywords
55288	Articles
62438	Press releases

Headlines Articles Press releases Sonnet BioTherapeutics, Inc.

Home
Companies
Sonnet BioTherapeutics, Inc.

BRIEF

published on 05/22/2024 at 13:05, 5 months 29 days ago

Sonnet BioTherapeutics annonce un examen des alternatives stratégiques

Sonnet BioTherapeutics Valeur Pour Les Actionnaires Examen Stratégique Marchés Des Capitaux Chardan Médicaments Immunothérapeutiques
BRIEF

published on 05/22/2024 at 13:05, 5 months 29 days ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

Strategic Review Sonnet BioTherapeutics Chardan Capital Markets Stockholder Value Immunotherapeutic Drugs
PRESS RELEASE

published on 05/22/2024 at 13:00, 5 months 29 days ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. initiates review of strategic alternatives to maximize stockholder value with financial advisor Chardan Capital Markets. Evaluation may lead to various strategic transactions but no definitive decisions made yet

Strategic Alternatives FHAB Technology Sonnet BioTherapeutics Holdings Inc. Chardan Capital Markets Immunotherapeutic Drugs
BRIEF

published on 05/20/2024 at 15:20, 6 months ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Clinical Trials Cancer Treatment Immunotherapy Sonnet BioTherapeutics SON-1010
BRIEF

published on 05/20/2024 at 15:20, 6 months ago

Sonnet BioTherapeutics annonce des données cliniques mises à jour pour SON-1010

Immunothérapie Essais Cliniques Sonnet BioTherapeutics FILS-1010 Traitement Du Cancer
PRESS RELEASE

published on 05/20/2024 at 15:15, 6 months ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics reports positive safety and efficacy data from Phase 1 clinical trials of SON-1010, a novel immunotherapeutic drug for solid tumors, demonstrating extended half-life and clinical benefit in patients

Solid Tumors Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug Phase 1 Clinical Trials
BRIEF

published on 05/14/2024 at 22:20, 6 months 6 days ago

Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités

Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF

published on 05/14/2024 at 22:20, 6 months 6 days ago

Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates

Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
PRESS RELEASE

published on 05/14/2024 at 22:15, 6 months 6 days ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN

Financial Results Biopharmaceutical Clinical Trial Sonnet BioTherapeutics Safety Data
BRIEF

published on 05/06/2024 at 13:05, 6 months 14 days ago

Sonnet BioTherapeutics to Present at EF Hutton Annual Global Conference

Biopharmaceuticals Sonnet BioTherapeutics Investor Meetings EF Hutton Conference Innovative Drugs

Accesswire

Published on 11/21/2024 at 10:03, 1 hour 28 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 31 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 31 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 56 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 11 hours 6 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:01, 30 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 31 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 35 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 1 minute ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 1 hour 26 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 33 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 24 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 11 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE